Imagine treating a serious eye condition as easily as taking a digital photo. Instead of a complex surgery requiring a top specialist, this tool uses a laser to lower eye pressure by just pressing a button. It's a non-contact treatment that takes only seconds, making it safe and fast for everyone.
Glaucoma care suffers from a shortage of specialists and poor patient compliance with medication. Current laser treatments are often too complex or time-consuming for general practitioners to perform.
The Eagle device, an automated, non-contact laser system for Direct Selective Laser Trabeculoplasty. An improved version was designed and prototyped as part of deliverable D14.
If you are a private clinic dealing with long patient waitlists for glaucoma specialists — this project developed the Eagle device that allows any ophthalmologist to deliver treatment in seconds. This increases the number of patients treated per day without needing rare specialist skills.
If you are an optometry provider dealing with limited treatment options for ocular hypertension — this project developed a non-contact laser system that is intuitive and simple. It enables eye care providers to offer primary treatment that was previously reserved for surgeons.
If you are a distributor dealing with high-cost, complex surgical equipment — this project developed a commercially viable product with a focus on reducing COGS. It provides a high-margin, automated tool for the EU market.
The project specifically aimed to increase profit margins by reducing the product's COGS through advanced production and automatic testing tools. Based on available project data, the goal was to lower the cost of critical components.
Yes, the project focused on establishing a commercial value chain and a controlled launch in 10 ophthalmic centers. It includes the development of automatic testing tools for production.
The project included a specific work package for IPR management to protect the technology during its commercialization and scale-up phase.
The project is focused on obtaining mandatory regulatory approvals for selling the device in various markets following the initial launch in Europe.
The project planned a controlled launch in 2023 across 10 ophthalmic centers led by key opinion leaders.
The project is led by a single SME, BELKIN VISION LTD from Israel. With a 100% industry ratio and no university or research partners, the consortium is lean and focused entirely on commercialization, regulatory approval, and market entry rather than basic research.
Contact BELKIN VISION LTD regarding the Eagle device commercial launch.
Contact us to find distribution partners for automated laser glaucoma care.
